A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects

Trial Profile

A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Suvratoxumab (Primary)
  • Indications Pneumonia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SAATELLITE
  • Sponsors MedImmune
  • Most Recent Events

    • 23 Oct 2017 Planned End Date changed from 14 Oct 2019 to 14 Jun 2019.
    • 23 Oct 2017 Planned primary completion date changed from 14 Oct 2019 to 14 Jun 2019.
    • 06 Feb 2017 Planned End Date changed from 1 Aug 2019 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top